Last updated: March 4, 2026
What is the drug associated with NDC 57237-0051?
NDC 57237-0051 corresponds to Otezla (apremilast), manufactured by Amgen Inc. It is approved for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet’s disease.
Market Overview
Current Market Size
The global psoriatic arthritis market was valued at approximately USD 3.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.2% through 2030. The increasing prevalence of psoriasis and psoriatic arthritis, along with a shift towards targeted therapies, fuels market expansion.
Competitive Landscape
Key competitors include:
- Humira (adalimumab, AbbVie)
- Cosentyx (secukinumab, Novartis)
- Taltz (ixekizumab, Eli Lilly)
- Skyrizi (risankizumab, AbbVie)
- Stelara (ustekinumab, Janssen)
Otezla is positioned as an oral, non-biologic therapy, which appeals to patients reluctant to use injectable treatments.
Regulatory Status and Approvals
- U.S. FDA approval: 2014
- Additional approvals: European Medicines Agency (EMA), 2015
- Expanded indications: psoriatic arthritis, psoriasis, Behçet’s disease
Sales Data
Amgen reported $733 million in Otezla sales for 2022, a 2% decrease from prior year, attributable to biosimilar competition in some markets and market saturation.
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP): Approximately USD 3,200–3,700 per month
- Average sales price (ASP): Slightly lower, around USD 2,900–3,200 per month
- Patient out-of-pocket: Typically USD 40–USD 70 per month, under insurance programs
Pricing Dynamics
- Biosimilar and generic entrants, though limited for non-biologics like apremilast, exert downward pressure
- Price reductions of 10–15% observed over two years in some markets
- Reimbursement policies influence net prices; preferential formulary placement can alter access and sales volume
Future Price Projections (2023–2027)
| Year |
Estimated Price Range |
Factors Influencing Price |
| 2023 |
USD 2,900 – USD 3,200 |
Market saturation, biosimilar dynamics |
| 2024 |
USD 2,800 – USD 3,150 |
Continued biosimilar competition, policy shifts |
| 2025 |
USD 2,700 – USD 3,000 |
Increased biosimilar entries, patent expiry in some regions |
| 2026 |
USD 2,600 – USD 2,950 |
Further biosimilar proliferation, formulary adjustments |
| 2027 |
USD 2,500 – USD 2,900 |
Market stabilization, potential new indications |
Factors Affecting Price and Market Penetration
- Patent expiration scheduled for 2028 for some jurisdictions
- Entry of biosimilar competitors targeting biologicals, less so for apremilast
- Demand growth driven by prevalence rates and expanded indications
- Reimbursement policies, especially in the U.S. and EU
Market Risks and Opportunities
Risks
- Biosimilar and generic competition
- Changes in reimbursement policies
- Regulatory restrictions affecting access
- Evolving treatment guidelines favoring biologics over oral agents
Opportunities
- Expansion into new markets and indications
- Strategic pricing to retain market share
- Differentiation through formulations or combination therapies
Key Takeaways
- The psoriatic arthritis market is expanding, with Otezla holding a significant share as an oral non-biologic option.
- Prices are declining gradually due to market saturation and biosimilar threats, with projections suggesting stability around USD 2,500–3,200 per month through 2027.
- Sales growth faces headwinds from biosimilar competitors and policy adjustments but benefits from steady prevalence rates and new indications.
- Future growth hinges on market penetration in emerging regions and potential repurposing of the drug for additional indications.
FAQs
1. How does Otezla compare to biologics in terms of efficacy?
Otezla has demonstrated comparable efficacy for certain patient populations but generally shows a different safety and tolerability profile. Biologics tend to have higher efficacy in severe cases.
2. What is the patent status of apremilast?
Patents for Otezla expire in 2028 in the U.S., opening potential for biosimilar or generic entry thereafter.
3. Are biosimilars applicable to Otezla?
No, biosimilars are specific to biologic drugs; as a small molecule, apremilast faces different competition dynamics.
4. What regulatory challenges could impact price or market access?
Changes in reimbursement policies or safety regulations could impact prescribing patterns and market share.
5. What regions present growth opportunities?
Emerging markets such as China, India, and Southeast Asia offer expanding patient populations and increasing treatment access.
Sources
[1] IQVIA. (2022). Global Markets for Psoriatic Arthritis.
[2] Amgen Inc. (2022). Otezla (apremilast) sales report.
[3] EvaluatePharma. (2022). Drug Market Outlook.
[4] European Medicines Agency. (2015). Otezla approval summary.
[5] U.S. FDA. (2014). Otezla (apremilast) approval documentation.
